Regimen | No. of ALL | Mean age (range) | Donor | Stem cell source | Disease status at HSCT | Survival rate | Relapse rate | TRM/NRM | aGVHD | cGVHD | Remarks | Reference |
---|---|---|---|---|---|---|---|---|---|---|---|---|
ETP 60 mg/kg × 1 + TBI 1.2 Gy × 11 | 5 | 28 (23–45) | MRD | BM | CR1: 4 | OS: 60 % (≧171 d) | 0 % | 40 % | 50 % (gr.≧II: 33 %) | ND | Intensified conditioning regimens followed by allogeneic HSCT were a preferred treatment modality for Ph + ALL according to a retrospective sutdy. | Forman SJ, et al. Blood 1987; 70:587 |
ETP 60 mg/kg × 1 + TBI 7.5 Gy × 1 | 1 | Non-CR: 6 | ||||||||||
CY 100 mg/kg × 1 + TBI 1.2 Gy × 11 | 3 | |||||||||||
BU 1 mg/kg × 16 + CY 60 mg/kg × 1 | 1 | |||||||||||
BU + CY +TBI | 67 | 28 (5–49) | MRD | BM | CR1: 33 | 2-Y DFS: 38 % | 34 % | CR1: 42 % | Gr.≧II: 24 % | 33 % | Allogeneic HSCT was feasible for Ph+ ALL patients according to a retrospective study using IBMTR data. The dose of conditioning regimens was not specified. | Barrett AJ, et al. Blood 1992; 79:3067. |
Rel: 22 | 2-Y DFS: 41 % | 32 % | Rel: 40 % | : 38 % | 31 % | |||||||
IF: 12 | 2-Y DFS: 25 % | 57 % | IF : 42 % | : 45 % | 22 % | |||||||
CY 60 mg/kg × 2 + TBI 1.2 Gy × 11 (for patients ≧18 y) | 15 | 25 (17–51) | MUD | BM | CR1: 7 | 2-Y DFS: 49 % | 29 % | 22 % | 100 % (gr.≧II: 75 %) | 62 % (ext. 54 %) | Unrelated HLA-matched donors were useful when related HLA-matched donors were not found in a retrospective study. | Sierra J, et al. Blood 1997; 90:1410. |
CY 60 mg/kg × 2 + TBI 1.2 Gy × 12 (for children) | 3 | >CR1: 1 | ||||||||||
Non-CR: 10 | ||||||||||||
ETP 50 mg/kg × 1 + TBI 1.2 Gy × 11+/–CY 60 mg/kg x 2 | 22 | 30 (6–42) | MRD | BM/PB | CR1 | 3-Y DFS: all 65 % | 12 % | 30 % | 65 % | 65 % | The relatively low relapse rate might reflect the enhanced anti-leukemic activity of ETP/TBI compared to other conditioning regimens in a retrospective study. | Snyder DS, et al. Leukemia 1999; 13:2053. |
CY 60 mg/kg × 2 + TBI 1.2 Gy × 11 | 1 | <1992 : 45 % | ||||||||||
≧1992: 81 % | ||||||||||||
ETP 50 mg/kg × 1 +CY 60 mg/kg × 2 +TBI 2 Gy × 6 or TBI 10 Gy × 1 | 74 | 42 (17–56) | MRD: 43 | BM | CR1 | 2-Y OS: 37 % | 40 % | 67 % | ND | ND | Allogeneic HSCT in CR1 was the best treatment option in Ph+ ALL according to a prospective study. Outcome was better in bcr/abl transcript-negative patients than in bcr-abl transcript-positive ones. The 2-Y OS, relapse, and TRM rates were 26 %, 74 %, and 91 %, respectively in 23 cases of autologous HSCT. | Dombret H, et al. Blood 2002;100:2357. |
MUD: 8 | 2-Y OS: 63 % | 25 % | 38 % | ND | ND | |||||||
CY 60 m/kg × 2 + TBI 2Gy × 6 (for adults) | Adults: 102 | 35 (1–53) | MRD: 79 | BM/PB | CR1: 76 | 2-Y OS: all 37 % | 44 % | 38 % | Adults Gr.≧II: 52 % | 43 % (ext.: 17 %) | A better outcome was correlated with remission status at transplant in a prospective study. The relapse rate decreased with the occurrence of acute GVHD. Bcr/abl transcript-positivity did not correlate to relapse rate. | Espérou H, et al. Bone Marrow Transplant. 2003;31:909. |
Ara-C 3 g/m2 × 4 or 6 + Mel 140 mg/m2 × 1 +TBI 2 Gy × 6 (for children) | Children: 19 | MUD: 42 | >CR1: 45 | CR1: 50 % | 37 % | Children Gr.≧II: 53 % | 39 % (ext.: 8 %) | |||||
CY 60 mg/kg × 2 + TBI 2 Gy × 6 | 166 | 37 (16–59) | MRD: 136 | BM: 167 | CR1: 93 | 5-Y OS | N.D. | N.D. | N.D. | N.D. | Allogeneic HSCT was the only procedure with curative potential for Ph+ ALL according to a retrospective study. Pre-transplant disease status was an important factor for better survival. Extensive cGVHD correlated with a better outcome, while severe aGVHD did not. | Yanada M. et al. Bone Marrow Transplant. 2005;36:867. |
Non-TBI | 31 | MUD: 61 | PB: 24 | :>CR1 19 | CR1: 34 % | |||||||
BM + PB: 6 | Non-CR: 85 | >CR1: 21 % | ||||||||||
5-Y OS | ||||||||||||
TBI (n = 166): 25 % | ||||||||||||
Non-TBI (n = 31): 8 % | ||||||||||||
ETP 60 mg/kg × 1 +TBI 1.2 Gy × 11 | 67 | 36 (2–57) | MRD | BM: 43 | CR1:49 | 10-Y OS | CR1: 31 % | 49 % (gr.≧II: 35 %) | 38 % (ext.: 13 %) | Disease status at the time of HSCT was important according to a retrospective study. ETP + TBI with or without CY conferred long-term survival. Seventeen patients received imatinib before HSCT and received the drug after HSCT as well. | Laport GG, et al.: Blood 2008;112:903. | |
ETP 60 mg/kg × 1 + CY 60 mg/kg × 2 + TBI 1.2 Gy × 11 | 11 | PB: 36 | >CR1:30 | CR1: 48 % | CR1: 28 % | >CR1: 54 % | ||||||
ETP 60 mg/kg × 1+BU 1 mg/kg × 16 +TBI 1.2 Gy × 11 | 1 | >CR1: 29 % | >CR1: 41 % |